HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes.

AbstractAIMS/HYPOTHESIS:
Emerging evidence suggests that in addition to hyperglycaemia, dyslipidaemia could represent a contributing pathogenetic factor to diabetic neuropathy, while obesity and insulin resistance play a role in the development of diabetic cardiac autonomic neuropathy (CAN) characterised by reduced heart rate variability (HRV), particularly in type 2 diabetes. We hypothesised that distinct lipid metabolites are associated with diminished HRV in recent-onset type 2 diabetes rather than type 1 diabetes.
METHODS:
We analysed 127 plasma lipid metabolites (11 acylcarnitines, 39 NEFA, 12 sphingomyelins (SMs), 56 phosphatidylcholines and nine lysophosphatidylcholines) using MS in participants from the German Diabetes Study baseline cohort recently diagnosed with type 1 (n = 100) and type 2 diabetes (n = 206). Four time-domain HRV indices (number of normal-to-normal (NN) intervals >50 ms divided by the number of all NN intervals [pNN50]; root mean square of successive differences [RMSSD]; SD of NN intervals [SDNN]; and SD of differences between adjacent NN intervals) and three frequency-domain HRV indices (very-low-frequency [VLF], low-frequency [LF] and high-frequency [HF] power spectrum) were computed from NN intervals recorded during a 3 h hyperinsulinaemic-euglycaemic clamp at baseline and in subsets of participants with type 1 (n = 60) and type 2 diabetes (n = 95) after 5 years.
RESULTS:
In participants with type 2 diabetes, after Bonferroni correction and rigorous adjustment, SDNN was inversely associated with higher levels of diacyl-phosphatidylcholine (PCaa) C32:0, PCaa C34:1, acyl-alkyl-phosphatidylcholine (PCae) C36:0, SM C16:0 and SM C16:1. SD of differences between NN intervals was inversely associated with PCaa C32:0, PCaa C34:1, PCaa C34:2, PCae C36:0 and SM C16:1, and RMSSD with PCae C36:0. For VLF power, inverse associations were found with PCaa C30:0, PCaa C32:0, PCaa C32:1, PCaa C34:2 and SM C16:1, and for LF power inverse associations were found with PCaa C32:0 and SM C16:1 (r = -0.242 to r = -0.349; p ≤ 0.0005 for all correlations). In contrast, no associations of lipid metabolites with measures of cardiac autonomic function were noted in participants recently diagnosed with type 1 diabetes. After 5 years, HRV declined due to ageing rather than diabetes, whereby prediction analyses for lipid metabolites were hampered.
CONCLUSIONS/INTERPRETATION:
Higher plasma levels of specific lipid metabolites are closely linked to cardiac autonomic dysfunction in recent-onset type 2 diabetes but not type 1 diabetes, suggesting a role for perturbed lipid metabolism in the early development of CAN in type 2 diabetes. Graphical abstract.
AuthorsDan Ziegler, Alexander Strom, Klaus Straßburger, Birgit Knebel, Gidon J Bönhof, Jörg Kotzka, Julia Szendroedi, Michael Roden, German Diabetes Study group
JournalDiabetologia (Diabetologia) Vol. 64 Issue 2 Pg. 458-468 (02 2021) ISSN: 1432-0428 [Electronic] Germany
PMID33084971 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Fatty Acids, Nonesterified
  • Lysophosphatidylcholines
  • Phosphatidylcholines
  • Sphingomyelins
  • acylcarnitine
  • Carnitine
Topics
  • Adult
  • Autonomic Nervous System Diseases (blood, etiology, physiopathology)
  • Carnitine (analogs & derivatives, blood)
  • Diabetes Mellitus, Type 1 (blood, complications)
  • Diabetes Mellitus, Type 2 (blood, complications)
  • Diabetic Neuropathies (blood, etiology, physiopathology)
  • Dyslipidemias (blood)
  • Fatty Acids, Nonesterified (blood)
  • Female
  • Glucose Clamp Technique
  • Heart Rate
  • Humans
  • Insulin Resistance
  • Lipid Metabolism
  • Lipidomics
  • Lysophosphatidylcholines (blood)
  • Male
  • Middle Aged
  • Obesity (blood)
  • Phosphatidylcholines (blood)
  • Sphingomyelins (blood)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: